Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD: Odevixibat in Children With Biliary Atresia Post-Kasai
2019-003807-37Phase 3Active
- Sponsor
- Albireo Pharma
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in biliary atresia comparing Odevixibat once daily with Placebo once daily (2 arms). Primary endpoint: Native liver survival at 104 weeks. Started Apr 2020; status: active.
02
Drugs
odevixibat
03
Conditions
biliary atresia
Beyond the preview
Go deeper on 2019-003807-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003807-37.